Federal Register of Legislation - Australian Government

Primary content

PB 93 of 2021 Determinations/Health as made
This instrument amends the National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) by adding three drugs to F1 in addition to removing one listed drug from F1 as it is no longer Pharmaceutical Benefits Scheme listed. It also makes amendments to rectify 10 administrative errors that occurred on 1 April 2021.
Administered by: Health
Registered 31 Aug 2021
Tabling HistoryDate
Tabled HR01-Sep-2021
Tabled Senate02-Sep-2021
To be repealed 11 Feb 2022
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 93 of 2021

 

National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 6)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following determination.

Dated               27 August 2021                      

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 


Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)                2

 

 


1  Name

                   This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 6).

                   This instrument may also be cited as PB 93 of 2021.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 September 2021.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 85AB(1) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1  Schedule 1, after item dealing with Apraclondine

insert:

Apremilast

2  Schedule 1, after item dealing with Carfilzomib

insert:

Cariprazine

3  Schedule 1, after item dealing with Dimethyl fumarate

omit:

Diptheria and tetanus vaccine, adsorbed, diluted for adult use

insert:

Diphtheria and tetanus vaccine, adsorbed, diluted for adult use

4  Schedule 1, after item dealing with Insulin neutral

omit:

Interferon alfa-2a 

5  Schedule 1, after item dealing with Lapatinib

insert:

Ledipasvir with sofosbuvir

6  Schedule 1, after item dealing with Mepolizumab

omit:

Mercaptopurine

7  Schedule 1, after item dealing with Mesna

omit:

Methenamine

8  Schedule 1, after item dealing with Nystatin

insert:

Obeticholic acid 

9  Schedule 1, after item dealing with Ponatinib  

omit:

Posaconazole 

 

10  Schedule 1, after item dealing with Praziquantel  

insert:

Prednisolone acetate

11  Schedule 1, after item dealing with Protein formula with carbohydrate, fat, vitamins and minerals

insert:

Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A

12  Schedule 1, after item dealing with Secukinumab  

insert:

Selexipag 

13  Schedule 1, after item dealing with Sodium phenylbutyrate     

omit:

Sofosbuvir

insert:

Sofosbuvir with velpatasvir

14  Schedule 2, after item dealing with Memantine  

insert:

Mercaptopurine 

15  Schedule 2, after item dealing with Methadone  

insert:

Methenamine

16  Schedule 2, after item dealing with Polyvinyl alcohol  

insert:

Posaconazole